Floatz logo

Bxcl501

Psychomotor Agitation

BioXcel Therapeutics IncPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Psychomotor Agitation cohort.

Asset / SponsorPhaseRating
Paliperidone Palmitate 3-Month Formulation
Janssen Cilag N.V./S.A.
Phase 4BB
Cipralex
University of Rochester
Phase 4BB
Loxapine
Lee's Pharmaceutical Limited
Phase 3B
PRAZOSIN
University of Washington
N/AD

Same molecule, other indications

Bxcl501 is also rated in:

Pain, ChronicDormant
A
Indicative ·
80 / 100
View asset →
Agitation,PsychomotorDormant
A
Indicative ·
80 / 100
View asset →
schizophreniform disorderDormant
A
Indicative ·
80 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →